Twist Bioscience Reports 17% Revenue Growth for Q1 Fiscal 2026

Details

DNA Synthesis and Protein Solutions revenue grew by 27% to about $51.1 million, and NGS Applications revenue grew to around $52.6 million, ahead of guidance. CEO Emily M. Leproust noted strong start to the fiscal year and expected momentum in the NGS segment. The company will release full financial results and host a conference call on February 2, 2026.

Items reported

About Twist Bioscience Corporation

Twist Bioscience Corporation is a pioneering biotechnology firm revolutionizing the field of synthetic DNA. The company's primary function is to produce synthetic DNA using a proprietary silicon-based manufacturing platform, enabling the creation of high-quality, accurate, and cost-effective DNA at scale. Twist Bioscience's innovations impact multiple sectors, including pharmaceuticals, industrial chemicals, agriculture, and data storage, offering transformative solutions in drug development, crop protection, and genomic research. By leveraging its proprietary DNA synthesis platform, Twist Bioscience plays a vital role in the broader biotechnology market, facilitating advancements that drive progress in personalized medicine and sustainable practices. With its cutting-edge technology, the company provides researchers and businesses with access to a wide array of DNA products and solutions essential for scientific discovery and technological innovation, underpinning its significance in the expanding biotech landscape.